Mallory–Denk Bodies Are Associated With Outcomes and Histologic Features in Patients With Chronic Hepatitis C  Mina O. Rakoski, Morton B. Brown, Robert J. Fontana, Herbert L. Bonkovsky, Elizabeth M. Brunt, Zachary D. Goodman, Anna S. Lok, M. Bishr Omary  Clinical Gastroenterology and Hepatology  Volume 9, Issue 10, Pages 902-909.e1 (October 2011) DOI: 10.1016/j.cgh.2011.07.006 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Study design. Cross-sectional analysis (n = 1050) and longitudinal analysis (n = 844). Clinical Gastroenterology and Hepatology 2011 9, 902-909.e1DOI: (10.1016/j.cgh.2011.07.006) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 (A) Representative H&E staining of a liver biopsy specimen from a patient with CHC (arrow, hepatocyte with a ring-like collection of MDBs). (B) Percentage of patients whose baseline biopsies had MDBs present by levels of fibrosis (3–6), zone 3 pericellular fibrosis (0–2), steatosis (0–4), and inflammation (3–12). P < .001 for each. Clinical Gastroenterology and Hepatology 2011 9, 902-909.e1DOI: (10.1016/j.cgh.2011.07.006) Copyright © 2011 AGA Institute Terms and Conditions

Figure 3 Kaplan–Meier analysis. Time from follow-up biopsy to first clinical event in patients with MDB gain vs no MDB gain. MDB gain was assessed at time of follow-up biopsy. Therefore, patients were excluded from this analysis if the first clinical event occurred prior to follow-up biopsy, resulting in exclusion of 3 and 62 patients with MDB gain and no MDB gain, respectively. Clinical Gastroenterology and Hepatology 2011 9, 902-909.e1DOI: (10.1016/j.cgh.2011.07.006) Copyright © 2011 AGA Institute Terms and Conditions